A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients with Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
- Registry ID
- EUCTR2004-001907-36
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Merck Sharp & Dohme Limited
- Start date
- 2005-03-18
- Completion date
- 2006-07-31
- Last update
- 2026-08-16
Conditions
- Relapsed Diffuse Large B-Cell Lymphoma
Summary
To determine the anti-tumor effectiveness of oral suberoylanilide hydroxamic acid (SAHA) as measured by overall objective response rate (ORR) in patients with relapsed DLBCL (de novo or transformed).
Locations
View on source registry